Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

15.2%

94 terminated/withdrawn out of 619 trials

Success Rate

80.6%

-5.9% vs industry average

Late-Stage Pipeline

7%

41 trials in Phase 3/4

Results Transparency

47%

182 of 390 completed trials have results

Key Signals

66 recruiting182 with results71 terminated23 withdrawn

Enrollment Performance

Analytics

Phase 2
183(32.0%)
N/A
175(30.6%)
Phase 1
170(29.8%)
Phase 3
29(5.1%)
Phase 4
12(2.1%)
Early Phase 1
2(0.4%)
571Total
Phase 2(183)
N/A(175)
Phase 1(170)
Phase 3(29)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (619)

Showing 20 of 619 trials
NCT07576725Phase 2Not Yet Recruiting

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

Role: lead

NCT07545291Not ApplicableNot Yet Recruiting

A Spiritual Health Intervention (PATH) for Improving Spiritual, Religious and Emotional Distress in Cancer Patients

Role: lead

NCT06034470Phase 1Active Not Recruiting

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Role: lead

NCT06909500Not ApplicableNot Yet Recruiting

A Digital Intervention (ACT on Vaping App) for Vaping Cessation in Young Adult E-Cigarette Users

Role: lead

NCT04829136Not ApplicableRecruiting

Sustained Oral Fiber Supplementation for Patients Undergoing Donor Stem Cell Transplantation for Hematological Malignancies

Role: lead

NCT07571018Not ApplicableNot Yet Recruiting

A Novel Mobile Health Intervention for Improving Tobacco Cessation Among Young Adults

Role: lead

NCT03670966Phase 1Recruiting

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Role: lead

NCT07561658Not ApplicableNot Yet Recruiting

TelePharm PrEP/PEP

Role: lead

NCT06934369Not ApplicableRecruiting

Improving Engagement in HIV and Cancer Care in Zimbabwe

Role: lead

NCT05701657Not ApplicableRecruiting

Nutrition for Precision Health, Powered by the All of Us

Role: collaborator

NCT07194980Phase 2Recruiting

Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Role: lead

NCT07459621Not ApplicableRecruiting

Evaluation of a Novel mHealth Intervention for People Who Are Ambivalent About Quitting Smoking

Role: collaborator

NCT07225985Phase 1Recruiting

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

Role: lead

NCT01231412Phase 3Completed

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

Role: lead

NCT04265950Phase 4Active Not Recruiting

Establishing Optimal Number of Doses for HPV Vaccination in Children and Adolescents Living With HIV, OPTIMO Trial

Role: lead

NCT07390916Not ApplicableNot Yet Recruiting

Feasibility Study Comparing One vs Two Probes for TA Among Cervical Cancer Screen Positive WLWH in C1001P-CS5 Rwanda

Role: lead

NCT07141407Not ApplicableRecruiting

Telephone-Based Coaching Sessions (TAC) to Improve Advance Care Planning Participation in Advanced Cancer Patients and Their Support Person

Role: lead

NCT01120353Recruiting

Childhood Cancer Survivor Study

Role: collaborator

NCT07052630Not ApplicableRecruiting

Patient Navigation and the Planning Advance Care Together Website to Improve Goals of Care Conversations in Hematopoietic Cell Transplant Survivors, IMPACT-HCT Trial

Role: lead

NCT07535008Not ApplicableRecruiting

Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease

Role: lead